Insuman Basal

Insulin human, the active ingredient in Insuman Basal, is an insulin presented as an injection solution for subcutaneous use. It provides a prolonged, steady release of insulin to help control blood glucose in individuals with type 1 or type 2 diabetes mellitus, targeting basal insulin requirements throughout the day.

GNH USA supplies Insuman Basal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved product for global distribution.

Insuman Basal is a long‑acting insulin used to manage blood glucose in diabetes mellitus. - Type 1 diabetes mellitus: provides basal insulin coverage to maintain fasting glucose levels. - Type 2 diabetes mellitus: contributes to basal glucose control as part of an insulin regimen.

The following adverse reactions have been reported with insulin therapy, including Insuman Basal.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if dose exceeds carbohydrate intake. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight associated with improved glycemic control.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Anaphylactic reaction: rare systemic allergic response with rash, breathing difficulty, or shock. - Insulin antibodies: development of antibodies that may alter insulin action.

When using Insuman Basal, several precautions should be observed to ensure safe and effective therapy. - Dose adjustment: monitor blood glucose regularly and adjust the dose as needed. - Renal impairment: use with caution and monitor glucose levels closely. - Elderly patients: may be more sensitive to hypoglycemia; start with lower doses. - Pregnancy and lactation: consider only if benefits outweigh potential risks. - Concomitant medications: review other drugs that may affect glucose control. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Basal may interact with other medicines, altering its glucose‑lowering effect or increasing adverse reaction risk.

Major Interactions (Avoid): - Sulfonylureas: combined use can increase risk of severe hypoglycemia. - Beta‑blockers: may mask typical hypoglycemia symptoms, requiring closer monitoring. - Systemic corticosteroids: can raise blood glucose, often necessitating higher insulin doses.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, monitor glucose levels. - Thiazide diuretics: may increase blood glucose, observe for hyperglycemia. - Alcohol: can cause delayed hypoglycemia, advise patients to consume cautiously.